Study of the adjuvant activity of new MDP derivatives and purified saponins and their influence on HIV-1 replication in vitro.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Vaccine

• Publication date

  1997-08-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0264-410X(97)00065-0PMID 9302764
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of a single-shot subunit vaccine for HIV-1.

  1997cited by this paper
• Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations.

  1995cited by this paper
• Effects of muramyl dipeptide derivatives as adjuvants on the induction of antibody response to recombinant hepatitis B surface antigen.

  1995cited by this paper
• Cytokine-Containing Liposomes as Adjuvants for HIV Subunit Vaccines

  1995cited by this paper
• Adjuvant activity of QS-21 for experimental E. coli 018 polysaccharide vaccines.

  1995cited by this paper
• Antiviral activity of an immunomodulatory lipophilic desmuramyl dipeptide analog.

  1995cited by this paper
• Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function.

  1995cited by this paper
• Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice.

  1995cited by this paper
• Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160.

  1994cited by this paper
• Nef and Gag Synthetic Peptide Priming of Antibody Responses to HIV Type 1 Antigens in Mice and Primates

  1994cited by this paper
• Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons .

  1994cited by this paper
• Mechanisms behind the immune response induced by immunostimulating complexes.

  1994cited by this paper
• Mycobacterium tuberculosis and its purified protein derivative activate expression of the human immunodeficiency virus.

  1994cited by this paper
• Lipid matrix-based subunit vaccines: a structure-function approach to oral and parenteral immunization.

  1994cited by this paper
• Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines.

  1994cited by this paper
• Effect of MTP-PE liposomes and interleukin-7 on induction of antibody and cell-mediated immune responses to a recombinant HIV-envelope protein.

  1994cited by this paper
• Immunization with Lentivirus-Like Particles Elicits a Potent SIV-Specific Recall Cytotoxic T-Lymphocyte Response in Rhesus Monkeys

  1993cited by this paper
• Adjuvants--a balance between toxicity and adjuvanticity.

  1993cited by this paper
• Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1.

  1993cited by this paper
• Selection of a muramyl peptide based on its lack of activation of nuclear factor‐κB as a potential adjuvant for AIDS vaccines

  1992cited by this paper
• Synthetic immunoadjuvants: application to non-specific host stimulation and potentiation of vaccine immunogenicity.

  1992cited by this paper
• Status of immune‐based therapies in HIV infection and AIDS

  1992cited by this paper
• Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.

  1992cited by this paper
• Development of a vaccine for the prevention of AIDS, a critical appraisal.

  1992cited by this paper
• Immunogenicity and Toxicity Testing of an Experimental HIV-1 Vaccine in Nonhuman Primates

  1992cited by this paper
• The Control of the Antibody Isotype Response to Recombinant Human Immunodeficiency Virus gp120 Antigen by Adjuvants

  1992cited by this paper
• Adjuvanticity and ISCOM formation by structurally diverse saponins.

  1992cited by this paper
• The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.

  1991cited by this paper
• Optimal immunity to HIV--natural infection, vaccination, or both?

  1991cited by this paper
• Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.

  1991cited by this paper
• The Safety and Immunogenicity of a Human Immunodeficiency Virus Type 1 (HIV-1) Recombinant gp160 Candidate Vaccine in Humans

  1991cited by this paper
• Muramyl Dipeptide Inhibits Replication of Human Immunodeficiency Virus in Vitro

  1990cited by this paper
• Development of a new type of influenza subunit vaccine made by muramyldipeptide-liposome: enhancement of humoral and cellular immune responses.

  1990cited by this paper
• Characterization of Serum Antibody Responses to Recombinant HIV-1 gp160 Vaccine by Enzyme Immunoassay

  1990cited by this paper
• Exacerbation of human immunodeficiency virus infection in promonocytic cells by bacterial immunomodulators.

  1990cited by this paper
• Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.

  1990cited by this paper
• Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics

  1989cited by this paper
• Effect of N alpha-acetylmuramyl-L-alanyl-D-isoglutaminyl-N epsilon-stearoyl- L-lysine on resistance to herpes simplex virus type-1 infection in cyclophosphamide-treated mice.

  1989cited by this paper
• Effect of Nα-acetylmuramyl-l-alanyl-d-isoglutaminyl-Nϵ-stearoyl-l-lysine on resistance to herpes simplex virus type-1 infection in cyclophosphamide-treated mice

  1989cited by this paper
• The Serum Antibody Response Distributed in Subclasses and Isotypes after Intranasal and Subcutaneous Immunization with Influenza Virus Immunostimulating Complexes

  1988cited by this paper
• Antiviral activity of glycyrrhizin against varicella-zoster virus in vitro.

  1987cited by this paper
• Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III/LAV)].

  1987cited by this paper
• Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice.

  1985cited by this paper
• Muramyl peptides. Variation of somnogenic activity with structure

  1984cited by this paper
• Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse.

  1979cited by this paper
• Total synthesis and adjuvant activity of bacterial peptidoglycan derivatives.

  1975cited by this paper
• Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives.

  1974cited by this paper
• Methods in Carbohydrate Chemistry

  1965cited by this paper
• The Synthesis of 2-Acetamido-3-O-(D-1-carboxyethyl)-2-deoxy-α-D-glucose (N-Acetylmuramic Acid) and of Benzyl Glycoside Derivatives of 2-Amino-3-O-(D-1-carboxyethyl)-2-deoxy-D-glucose (Muramic Acid)1

  1963cited by this paper

• Development of semisynthetic saponin immunostimulants

  2024cites this paper
• Synthesis of α-Cyclooctyl- and α-Cyclopentadecylglycosides of N-Acetylmuramyl-L-Alanyl-D-Isoglutamine

  2018cites this paper
• CYTOTOXIC PROPERTIES OF TRITERPENE SAPONIN TAUROSID SX1 AND ITS EFFECT ON HUMAN IMMUNODEFICIENCY VIRUS AND INFLUENZA VIRUS INFECTION IN MICE.

  2018cites this paper
• Immunological aspects of using plant cells as delivery vehicles for oral vaccines

  2014cites this paper
• Immunoadjuvant and anti-inflammatory plant saponins: characteristics and biotechnological approaches towards sustainable production.

  2011cites this paper
• Comparative study of structurally related peptidoglycan monomer and muramyl dipeptide on humoral IgG immune response to ovalbumin in mouse.

  2010cites this paper
• Identification of SARS-COV Spike Protein-Derived and HLA-A2-Restricted Human CTL Epitopes by Using a New Muramyl Dipeptide-Derivative Adjuvant

  2010cites this paper
• Unleashing the therapeutic potential of NOD-like receptors

  2009cites this paper
• Advances in saponin-based adjuvants.

  2009cites this paper
• Development of novel carriers for transdermal delivery of peptides

  2009cites this paper
• Dialkylmethyl β-glycosides of N-acetylmuramyl-L-alanyl-D-isoglutamine: Synthesis and protective antiinfection and cytotoxic activities

  2008cites this paper
• A promising balanced Th1 and Th2 directing immunological adjuvant, saponins from the root of Platycodon grandiflorum.

  2008cites this paper
• An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2).

  2008cites this paper
• Immunological adjuvant activities of saponin extracts from the pods of Acacia concinna.

  2006cites this paper
• Synthesis and protective anti-infective action of anomeric lipophilic glycosides of N-acetylmuramyl-L-alanyl-D-isoglutamine

  2006cites this paper
• Synthesis and Protective Activity of β-Glycosides of N-Acetylmuramyl-L-Alanyl-D-Isoglutamine with Alkylalicyclic and Arylaliphatic Aglycons

  2005cites this paper
• N-Acetylmuramyl-L-Alanyl-D-Isoglutamine Glycosides: Effect of Glycoside Bond Configuration and Aglycone on Biological Activity

  2003cites this paper
• Synthesis of N-Acetylmuramyl-L-Alanyl-D-Isoglutamine Aryl β-Glycosides

  2001cites this paper
• Isolation and evaluation of immunological adjuvant activities of saponins from Polygala senega L.

  2000cites this paper
• Comparative study of the effects of peptidoglycan monomer and structurally related adamantyltripeptides on humoral immune response to ovalbumin in the mouse.

  2000cites this paper
• New age adjuvants and delivery systems for subunit vaccines

  2000cites this paper
• Natural food antimicrobial systems

  2000cites this paper
• [Synthesis and biological activity of anomeric muramoyldipeptide butylglycosides].

  1999cites this paper
• In vitro detection of antigen specific T lymphocyte subsets in cattle

  1998cites this paper